Pacira BioSciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $746.2M+6.4% YoYTTM through 30 Jun 2026
Net Income $14.6MTTM through 30 Jun 2026
Free Cash Flow $179.5MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 79.4% |
| EBITDA Margin | 14.1% |
| Operating Margin | 2.6% |
| Net Margin | 2.0% |
Returns
1.0%ROE
5.6%ROA
1.8%ROIC
Balance Sheet Health
Debt / Equity0.54x
Current Ratio4.54x
Net Debt$133.8M
Cash & Equivalents$205.9M
Quality Metrics
Altman Z-Score1.95
Piotroski F-Score8 / 9
FCF Margin24.1%
Rule of 4025.1
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $726.4M
Diluted EPS$0.35TTMFY2025: $0.16
Dividend
No dividend
Capital Allocation
R&D Spend$121.7M
Capex Intensity1.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| EXPAREL | $575.1M | +5.0% | View detailsExclusivity runway extended to 2039 following a favorable patent litigation settlement in April 2025. |
| ZILRETTA | $116.6M | -1.0% | View detailsPhase 3 registrational study in shoulder osteoarthritis pain completed enrollment in Q1 2026. |
| iovera° | $24.2M | +6.0% | View detailsRegistrational study in spasticity expected to read out in 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.